Deloitte December 18, 2019
Francesca Properzi

How will artificial intelligence (AI) drive the digital transformation of biopharma? At the 2019 Global Financial Times Pharmaceutical and Biotechnology conference in London last month, we launched Intelligent drug discovery: Powered by AI. This report—the second in a series—explores the rise of disruptive AI for drug discovery companies and the challenges and opportunities for biopharma in using AI technologies to help find new, more precise, and targeted treatments.1 This blog highlights the key takeaways from our report.

Accelerating drug discovery

Drug discovery is the process of identifying new medicines for treating or curing disease, which has led to many life-saving and life-enhancing clinical treatments. However, the process has historically been long, expensive, and often unsuccessful, with many unmet needs still...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Pharma, Technology
Global Inequities In Access To Drugs Costs Millions Of Lives Each Year
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
Why Conflicts Of Interest May Not Be As Bad As You Think (And Besides We All Have Them!)
11 drugs now in shortage

Share This Article